array(40) {
  [0]=>
  string(4) "4005"
  ["article_id"]=>
  string(4) "4005"
  [1]=>
  string(85) "AstraZeneca’s Tagrisso meets secondary endpoint in phase III lung cancer study"
  ["article_title"]=>
  string(85) "AstraZeneca’s Tagrisso meets secondary endpoint in phase III lung cancer study"
  [2]=>
  string(150) "The company has announced positive OS results from the phase III randomised, double-blinded and multi-centre trial of Tagrisso in previously-untreated"
  ["short_description"]=>
  string(150) "The company has announced positive OS results from the phase III randomised, double-blinded and multi-centre trial of Tagrisso in previously-untreated"
  [3]=>
  string(605) "
The company has announced positive OS results from the phase III randomised, double-blinded and multi-centre trial of Tagrisso in previously-untreated patients with locally-advanced or metastatic non-small cell lung 
&#nl
The post AstraZeneca’s Tagrisso meets secondary endpoint in phase III lung cancer study appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(605) "
The company has announced positive OS results from the phase III randomised, double-blinded and multi-centre trial of Tagrisso in previously-untreated patients with locally-advanced or metastatic non-small cell lung 
&#nl
The post AstraZeneca’s Tagrisso meets secondary endpoint in phase III lung cancer study appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(86) "https://www.pharmaceutical-business-review.com/news/astrazenecas-tagrisso-lung-cancer/"
  ["blog_url"]=>
  string(86) "https://www.pharmaceutical-business-review.com/news/astrazenecas-tagrisso-lung-cancer/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-08-14 10:54:57"
  ["create_at"]=>
  string(19) "2019-08-14 10:54:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4006"
  ["article_id"]=>
  string(4) "4006"
  [1]=>
  string(97) "Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer"
  ["article_title"]=>
  string(97) "Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer"
  [2]=>
  string(159) "The updated preliminary Phase 3 clinical data will serve as the basis for the anticipated initiation of the Company’s BLA submission in 4Q 2019 “A"
  ["short_description"]=>
  string(159) "The updated preliminary Phase 3 clinical data will serve as the basis for the anticipated initiation of the Company’s BLA submission in 4Q 2019 “A"
  [3]=>
  string(648) "
The updated preliminary Phase 3 clinical data will serve as the basis for the anticipated initiation of the Company’s BLA submission in 4Q 2019 “After two very positive 
&#nl
The post Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(648) "
The updated preliminary Phase 3 clinical data will serve as the basis for the anticipated initiation of the Company’s BLA submission in 4Q 2019 “After two very positive 
&#nl
The post Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(150) "https://www.pharmaceutical-business-review.com/news/sesen-bio-reports-data-update-from-phase-3-trial-for-high-risk-non-muscle-invasive-bladder-cancer/"
  ["blog_url"]=>
  string(150) "https://www.pharmaceutical-business-review.com/news/sesen-bio-reports-data-update-from-phase-3-trial-for-high-risk-non-muscle-invasive-bladder-cancer/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-08-14 10:54:57"
  ["create_at"]=>
  string(19) "2019-08-14 10:54:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4007"
  ["article_id"]=>
  string(4) "4007"
  [1]=>
  string(80) "Kala Pharmaceuticals receives FDA complete response letter for KPI-121 0.25% NDA"
  ["article_title"]=>
  string(80) "Kala Pharmaceuticals receives FDA complete response letter for KPI-121 0.25% NDA"
  [2]=>
  string(150) "The FDA indicated that efficacy data from an additional clinical trial will be needed to support a resubmission. Kala continues to enroll patients in "
  ["short_description"]=>
  string(150) "The FDA indicated that efficacy data from an additional clinical trial will be needed to support a resubmission. Kala continues to enroll patients in "
  [3]=>
  string(602) "
The FDA indicated that efficacy data from an additional clinical trial will be needed to support a resubmission. Kala continues to enroll patients in its ongoing STRIDE 3 
&#nl
The post Kala Pharmaceuticals receives FDA complete response letter for KPI-121 0.25% NDA appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(602) "
The FDA indicated that efficacy data from an additional clinical trial will be needed to support a resubmission. Kala continues to enroll patients in its ongoing STRIDE 3 
&#nl
The post Kala Pharmaceuticals receives FDA complete response letter for KPI-121 0.25% NDA appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(132) "https://www.pharmaceutical-business-review.com/news/kala-pharmaceuticals-receives-fda-complete-response-letter-for-kpi-121-0-25-nda/"
  ["blog_url"]=>
  string(132) "https://www.pharmaceutical-business-review.com/news/kala-pharmaceuticals-receives-fda-complete-response-letter-for-kpi-121-0-25-nda/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-08-14 10:54:57"
  ["create_at"]=>
  string(19) "2019-08-14 10:54:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4008"
  ["article_id"]=>
  string(4) "4008"
  [1]=>
  string(53) "Bayer to buy remaining stake in BlueRock Therapeutics"
  ["article_title"]=>
  string(53) "Bayer to buy remaining stake in BlueRock Therapeutics"
  [2]=>
  string(152) "The deal also includes an additional payment of $360m (£296.2m) based on achievement of pre-defined development milestones. The total investment in B"
  ["short_description"]=>
  string(152) "The deal also includes an additional payment of $360m (£296.2m) based on achievement of pre-defined development milestones. The total investment in B"
  [3]=>
  string(549) "
The deal also includes an additional payment of $360m (£296.2m) based on achievement of pre-defined development milestones. The total investment in BlueRock is valued at around $1bn (£823m), 
&#nl
The post Bayer to buy remaining stake in BlueRock Therapeutics appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(549) "
The deal also includes an additional payment of $360m (£296.2m) based on achievement of pre-defined development milestones. The total investment in BlueRock is valued at around $1bn (£823m), 
&#nl
The post Bayer to buy remaining stake in BlueRock Therapeutics appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/bayer-bluerock-therapeutics/"
  ["blog_url"]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/bayer-bluerock-therapeutics/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-08-14 10:54:57"
  ["create_at"]=>
  string(19) "2019-08-14 10:54:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4119"
  ["article_id"]=>
  string(4) "4119"
  [1]=>
  string(50) "Nanotechnology in Cancer: Engineering for Oncology"
  ["article_title"]=>
  string(50) "Nanotechnology in Cancer: Engineering for Oncology"
  [2]=>
  string(150) "Nanotechnology offers exciting opportunities in the fight against cancer. New technological breakthroughs have enabled innovative therapeutic applicat"
  ["short_description"]=>
  string(150) "Nanotechnology offers exciting opportunities in the fight against cancer. New technological breakthroughs have enabled innovative therapeutic applicat"
  [3]=>
  string(528) "Nanotechnology offers exciting opportunities in the fight against cancer. New technological breakthroughs have enabled innovative therapeutic applications of nanoparticles and have facilitated diagnostics at the nanoscale.&#nlAs examples, the delivery of RNA with nanoparticles (in the product patisiran), has been approved by EMA/FDA in 2018, while the first liquid biopsy for prostate cancer based on exosome analysis was launched in 2016.&#nlThis conference aims to bridge nanotechnolog…"
  ["description"]=>
  string(528) "Nanotechnology offers exciting opportunities in the fight against cancer. New technological breakthroughs have enabled innovative therapeutic applications of nanoparticles and have facilitated diagnostics at the nanoscale.&#nlAs examples, the delivery of RNA with nanoparticles (in the product patisiran), has been approved by EMA/FDA in 2018, while the first liquid biopsy for prostate cancer based on exosome analysis was launched in 2016.&#nlThis conference aims to bridge nanotechnolog…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(98) "
https://www.pharmiweb.com/event/nanotechnology-in-cancer-engineering-for-oncology                "
  ["blog_url"]=>
  string(98) "
https://www.pharmiweb.com/event/nanotechnology-in-cancer-engineering-for-oncology                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-08-14 10:55:45"
  ["create_at"]=>
  string(19) "2019-08-14 10:55:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4120"
  ["article_id"]=>
  string(4) "4120"
  [1]=>
  string(135) "Managing Your Complaints and Obstacles in Post-Market Requirements -- Results from Top Medical Device Observations During an Inspection"
  ["article_title"]=>
  string(135) "Managing Your Complaints and Obstacles in Post-Market Requirements -- Results from Top Medical Device Observations During an Inspection"
  [2]=>
  string(159) "Learning Objectives:&#nl&#nlUnderstand how to comply with complicated Compliant Handling, MDR and Recall requirements&#nlFirms MDR reporting and FDA's hand"
  ["short_description"]=>
  string(159) "Learning Objectives:&#nl&#nlUnderstand how to comply with complicated Compliant Handling, MDR and Recall requirements&#nlFirms MDR reporting and FDA's hand"
  [3]=>
  string(530) "Learning Objectives:&#nl&#nlUnderstand how to comply with complicated Compliant Handling, MDR and Recall requirements&#nlFirms MDR reporting and FDA's handling of reports&#nlCompany preparation in the event of a Recall, recall strategy, notification letter and communicating with the FDA&#nlMinimize your risk of regulatory enforcement actions&#nlAssist with the creation and maintenance of effective procedures for handling complaints, reportable events and recalls&#nlUnderstand the relationship and interaction …"
  ["description"]=>
  string(530) "Learning Objectives:&#nl&#nlUnderstand how to comply with complicated Compliant Handling, MDR and Recall requirements&#nlFirms MDR reporting and FDA's handling of reports&#nlCompany preparation in the event of a Recall, recall strategy, notification letter and communicating with the FDA&#nlMinimize your risk of regulatory enforcement actions&#nlAssist with the creation and maintenance of effective procedures for handling complaints, reportable events and recalls&#nlUnderstand the relationship and interaction …"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(181) "
https://www.pharmiweb.com/event/managing-your-complaints-and-obstacles-in-post-market-requirements-results-from-top-medical-device-observations-during-an-inspection                "
  ["blog_url"]=>
  string(181) "
https://www.pharmiweb.com/event/managing-your-complaints-and-obstacles-in-post-market-requirements-results-from-top-medical-device-observations-during-an-inspection                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-08-14 10:55:45"
  ["create_at"]=>
  string(19) "2019-08-14 10:55:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4121"
  ["article_id"]=>
  string(4) "4121"
  [1]=>
  string(63) "20th Edition of International Conference on Clinical Nephrology"
  ["article_title"]=>
  string(63) "20th Edition of International Conference on Clinical Nephrology"
  [2]=>
  string(150) ": 20th Edition of International Conference on Clinical Nephrology symposium targets the undiscovered phases of Nephrology research which gives an inim"
  ["short_description"]=>
  string(150) ": 20th Edition of International Conference on Clinical Nephrology symposium targets the undiscovered phases of Nephrology research which gives an inim"
  [3]=>
  string(524) ": 20th Edition of International Conference on Clinical Nephrology symposium targets the undiscovered phases of Nephrology research which gives an inimitable chance to researchers all over the world to participate, share and perceive new thoughts and also exploration work. Our theme “Exploring the new technologies in Clinical Nephrology” focuses on understanding the unknown facts of the Nephrology and its research. The two day conference embraces the workshops and keynote speech from some promine…"
  ["description"]=>
  string(524) ": 20th Edition of International Conference on Clinical Nephrology symposium targets the undiscovered phases of Nephrology research which gives an inimitable chance to researchers all over the world to participate, share and perceive new thoughts and also exploration work. Our theme “Exploring the new technologies in Clinical Nephrology” focuses on understanding the unknown facts of the Nephrology and its research. The two day conference embraces the workshops and keynote speech from some promine…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(112) "
https://www.pharmiweb.com/event/20th-edition-of-international-conference-on-clinical-nephrology                "
  ["blog_url"]=>
  string(112) "
https://www.pharmiweb.com/event/20th-edition-of-international-conference-on-clinical-nephrology                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-08-14 10:55:45"
  ["create_at"]=>
  string(19) "2019-08-14 10:55:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4122"
  ["article_id"]=>
  string(4) "4122"
  [1]=>
  string(51) "H27 Clinical Research for Non-Clinical Researchers "
  ["article_title"]=>
  string(51) "H27 Clinical Research for Non-Clinical Researchers "
  [2]=>
  string(171) "On this specific course you will learn how to;&#nl• Define clinical research&#nl• Understand key clinical research terms&#nl• Identify the key stakeholde"
  ["short_description"]=>
  string(171) "On this specific course you will learn how to;&#nl• Define clinical research&#nl• Understand key clinical research terms&#nl• Identify the key stakeholde"
  [3]=>
  string(390) "On this specific course you will learn how to;&#nl• Define clinical research&#nl• Understand key clinical research terms&#nl• Identify the key stakeholders in a typical project team&#nl• Summarise the responsibilities of key positions&#nl• Explain Serious Adverse Event Reporting&#nl• Recognise documents that may need to be kept in the Trial Master File"
  ["description"]=>
  string(390) "On this specific course you will learn how to;&#nl• Define clinical research&#nl• Understand key clinical research terms&#nl• Identify the key stakeholders in a typical project team&#nl• Summarise the responsibilities of key positions&#nl• Explain Serious Adverse Event Reporting&#nl• Recognise documents that may need to be kept in the Trial Master File"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(99) "
https://www.pharmiweb.com/event/h27-clinical-research-for-non-clinical-researchers                "
  ["blog_url"]=>
  string(99) "
https://www.pharmiweb.com/event/h27-clinical-research-for-non-clinical-researchers                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-08-14 10:55:45"
  ["create_at"]=>
  string(19) "2019-08-14 10:55:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4123"
  ["article_id"]=>
  string(4) "4123"
  [1]=>
  string(39) "PriMe Pharmaceutical Marketing Workshop"
  ["article_title"]=>
  string(39) "PriMe Pharmaceutical Marketing Workshop"
  [2]=>
  string(150) "This 1 day course provides attendees with an explanation behind concepts, tactics and trends within digital marketing and explains a process for integ"
  ["short_description"]=>
  string(150) "This 1 day course provides attendees with an explanation behind concepts, tactics and trends within digital marketing and explains a process for integ"
  [3]=>
  string(515) "This 1 day course provides attendees with an explanation behind concepts, tactics and trends within digital marketing and explains a process for integrating digital into the overall business strategy and marketing plan. The course also examines the perspective of the customer, other stakeholders including health professionals and external agencies and the unique challenges of implementing digital in the Pharma sector supported by real-life cases-studies to bring the theory and concepts to life.&#nl…"
  ["description"]=>
  string(515) "This 1 day course provides attendees with an explanation behind concepts, tactics and trends within digital marketing and explains a process for integrating digital into the overall business strategy and marketing plan. The course also examines the perspective of the customer, other stakeholders including health professionals and external agencies and the unique challenges of implementing digital in the Pharma sector supported by real-life cases-studies to bring the theory and concepts to life.&#nl…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(103) "
https://www.pharmiweb.com/event/prime-pharmaceutical-marketing-workshop-september-2019                "
  ["blog_url"]=>
  string(103) "
https://www.pharmiweb.com/event/prime-pharmaceutical-marketing-workshop-september-2019                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-08-14 10:55:45"
  ["create_at"]=>
  string(19) "2019-08-14 10:55:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4124"
  ["article_id"]=>
  string(4) "4124"
  [1]=>
  string(28) "BioPharm Americaâ„¢ 2019"
  ["article_title"]=>
  string(28) "BioPharm Americaâ„¢ 2019"
  [2]=>
  string(154) "BioPharm Americaâ„¢ is a unique partnering event that forms the nexus of discovery and realization. Now in its twelfth year, BioPharm America creates "
  ["short_description"]=>
  string(154) "BioPharm Americaâ„¢ is a unique partnering event that forms the nexus of discovery and realization. Now in its twelfth year, BioPharm America creates "
  [3]=>
  string(520) "BioPharm Americaâ„¢ is a unique partnering event that forms the nexus of discovery and realization. Now in its twelfth year, BioPharm America creates a robust exchange among hundreds of executives from venture capital firms, major pharmaceutical companies, academic institutions and biotechnology companies of every size and stage, from mature to startup. The event brings dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.&#nlA primary focus…"
  ["description"]=>
  string(520) "BioPharm Americaâ„¢ is a unique partnering event that forms the nexus of discovery and realization. Now in its twelfth year, BioPharm America creates a robust exchange among hundreds of executives from venture capital firms, major pharmaceutical companies, academic institutions and biotechnology companies of every size and stage, from mature to startup. The event brings dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.&#nlA primary focus…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(70) "
https://www.pharmiweb.com/event/biopharm-america-2019                "
  ["blog_url"]=>
  string(70) "
https://www.pharmiweb.com/event/biopharm-america-2019                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-08-14 10:55:45"
  ["create_at"]=>
  string(19) "2019-08-14 10:55:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4125"
  ["article_id"]=>
  string(4) "4125"
  [1]=>
  string(26) "Intelligent Health AI 2019"
  ["article_title"]=>
  string(26) "Intelligent Health AI 2019"
  [2]=>
  string(150) "Intelligent Health AI will once again bring together the global AI and health community in Switzerland to advance discussions on how AI can be used to"
  ["short_description"]=>
  string(150) "Intelligent Health AI will once again bring together the global AI and health community in Switzerland to advance discussions on how AI can be used to"
  [3]=>
  string(523) "Intelligent Health AI will once again bring together the global AI and health community in Switzerland to advance discussions on how AI can be used to prevent and solve some of the world’s greatest healthcare problems, and improve the health of the human race.&#nl&#nlThe event will gather a unique ecosystem of clinicians, C-suite executives in pharma, biotech and medtech, government ministers, regulators and technologists, to create a future where AI can revolutionise health across oncology, radiolo…"
  ["description"]=>
  string(523) "Intelligent Health AI will once again bring together the global AI and health community in Switzerland to advance discussions on how AI can be used to prevent and solve some of the world’s greatest healthcare problems, and improve the health of the human race.&#nl&#nlThe event will gather a unique ecosystem of clinicians, C-suite executives in pharma, biotech and medtech, government ministers, regulators and technologists, to create a future where AI can revolutionise health across oncology, radiolo…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(75) "
https://www.pharmiweb.com/event/intelligent-health-ai-2019                "
  ["blog_url"]=>
  string(75) "
https://www.pharmiweb.com/event/intelligent-health-ai-2019                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-08-14 10:55:45"
  ["create_at"]=>
  string(19) "2019-08-14 10:55:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4126"
  ["article_id"]=>
  string(4) "4126"
  [1]=>
  string(29) "Synthetic Biology Summit 2019"
  ["article_title"]=>
  string(29) "Synthetic Biology Summit 2019"
  [2]=>
  string(150) "Lexis proudly announces the conference Synthetic Biology Summit 2019 which is going to take place in London, UK during September 11-12, 2019. Lexis in"
  ["short_description"]=>
  string(150) "Lexis proudly announces the conference Synthetic Biology Summit 2019 which is going to take place in London, UK during September 11-12, 2019. Lexis in"
  [3]=>
  string(528) "Lexis proudly announces the conference Synthetic Biology Summit 2019 which is going to take place in London, UK during September 11-12, 2019. Lexis invites the experts from around the globe to attend the Synthetic Biology Summit to explore the theme “Significant and Potential uses of Synthetic Biology”.&#nl&#nlSynthetic biology is an interdisciplinary branch of both biology and engineering. It combines disciplines from within these domains, such as biotechnology, genetic engineering, molecular biolo…"
  ["description"]=>
  string(528) "Lexis proudly announces the conference Synthetic Biology Summit 2019 which is going to take place in London, UK during September 11-12, 2019. Lexis invites the experts from around the globe to attend the Synthetic Biology Summit to explore the theme “Significant and Potential uses of Synthetic Biology”.&#nl&#nlSynthetic biology is an interdisciplinary branch of both biology and engineering. It combines disciplines from within these domains, such as biotechnology, genetic engineering, molecular biolo…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(78) "
https://www.pharmiweb.com/event/synthetic-biology-summit-2019                "
  ["blog_url"]=>
  string(78) "
https://www.pharmiweb.com/event/synthetic-biology-summit-2019                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-08-14 10:55:45"
  ["create_at"]=>
  string(19) "2019-08-14 10:55:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}